Specifically, PIVOT-02 showed that although higher baseline levels of CD8+ T cell tumor infiltration corresponded with a response to BEMPEG + NIVO, there was only a trend towards baseline PD-L1 expression and response to treatment12. This evidence concerns the gene CD8A and neoplasm.